Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125959 | 0.86 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL4276906 | 0.86 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL7548158 | 0.86 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL9578575 | 0.86 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL6946501 | 0.86 | MAPT (0.69) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL6953681 | 0.85 | NNMT (0.59) | MAPTTP53TSHRPLA2G4BCYP3A4 | |
| SCHEMBL10662876 | 0.84 | MAPT (0.71) | MAPTTP53TSHRPLA2G4BRARB | |
| SCHEMBL7219864 | 0.84 | LMNA (0.62) | MAPTTSHRCYP2D6ALDH1A1HPGD | |
| SCHEMBL1680864 | 0.83 | NNMT (0.61) | MAPTTP53TSHRPLA2G4BCYP3A4 | |
| SCHEMBL9730460 | 0.81 | MAPT (0.40) | MAPTTP53TSHRPLA2G4BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6387606-B1 | SILVER HALIDE EMULSION AND COUPLER | EASTMAN KODAK COMPANY | 2002-05-14 | — | — | US | disclosed |
| US-20020051945-A1 | Photographic element, compound, and process | BEGLEY WILLIAM J (US) | 2002-05-02 | — | — | US | disclosed |
| US-20010014432-A1 | Photographic element, compound, and process | BEGLEY WILLIAM J (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1113328-A1 | Photographic element, compound, and process | EASTMAN KODAK COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-1113006-A1 | Process for the synthesis of 2,5-dicarbonamidophenolic couplers and benzoxazole derivatives as intermediates | EASTMAN KODAK COMPANY (US) | 2001-07-04 | — | — | EP | disclosed |
| US-6201125-B1 | REDUCING A 2-ALKYL-6-NITRO-BENZOXAZOLE TO FORM A 2-ALKYL-6-AMINO-BENZOXAZOLE IN WHICH THE 2-ALKYL GROUP IS UNBRANCHED AT THE ALPHA CARBON; COUPLERS | EASTMAN KODAK COMPANY | 2001-03-13 | — | — | US | disclosed |
| US-6197492-B1 | CYAN DYE HUE | EASTMAN KODAK COMPANY | 2001-03-06 | — | — | US | disclosed |
| US-6190850-B1 | CYAN ?NB COUPLER? THAT FORMS A DYE FOR WHICH THE LEFT BANDWIDTH (LBW) USING SPIN-COATING IS AT LEAST 5 NM LESS THAN THAT OF THE SAME DYE IN SOLUTION FORM | EASTMAN KODAK COMPANY | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020051945-A1 | Photographic element, compound, and process | BMI1, HBZ, ZKSCAN2 | MAPT 2420/4885TP53 3904/4885TSHR 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.